Debanjan Sarkar

Dr. Debanjan Sarkar


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2011 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
WZWeian Zhao
Weian Zhao
SSSebastian Schafer
Sebastian Schafer
JCJonghoon Choi
Jonghoon Choi
YYYvonne J. Yamanaka
Yvonne J. Yamanaka
MLMaria L. Lombardi
Maria L. Lombardi
JKJeffrey M. Karp
Jeffrey M. Karp
The ability to explore cell signalling and cell-to-cell communication is essential for understanding cell biology and developing effective therapeutics. However, it is not yet possible to monitor the interaction of cells with their environments in real time. Here, we show that a fluorescent sensor attached to a cell membrane can detect signalling molecules in the cellular environment. The sensor is an aptamer (a short length of single-stranded DNA) that binds to platelet-derived growth factor (PDGF) and contains a pair of fluorescent dyes. When bound to PDGF, the aptamer changes conformation and the dyes come closer to each other, producing a signal. The sensor, which is covalently attached to the membranes of mesenchymal stem cells, can quantitatively detect with high spatial and temporal resolution PDGF that is added in cell culture medium or secreted by neighbouring cells. The engineered stem cells retain their ability to find their way to the bone marrow and can be monitored in vivo at the single-cell level using intravital microscopy.

15 December 2011 in Blood
Verified
Journal Article
Closed access
PDF file
DSDebanjan Sarkar
Debanjan Sarkar
JSJoel A. Spencer
Joel A. Spencer
JPJoseph A. Phillips
Joseph A. Phillips
WZWeian Zhao
Weian Zhao
SSSebastian Schafer
Sebastian Schafer
JKJeffrey M. Karp
Jeffrey M. Karp
One of the greatest challenges in cell therapy is to minimally invasively deliver a large quantity of viable cells to a tissue of interest with high engraftment efficiency. Low and inefficient homing of systemically delivered mesenchymal stem cells (MSCs), for example, is thought to be a major limitation of existing MSC-based therapeutic approaches, caused predominantly by inadequate expression of cell surface adhesion receptors. Using a platform approach that preserves the MSC phenotype and does not require genetic manipulation, we modified the surface of MSCs with a nanometer-scale polymer construct containing sialyl Lewisx (sLex) that is found on the surface of leukocytes and mediates cell rolling within inflamed tissue. The sLex engineered MSCs exhibited a robust rolling response on inflamed endothelium in vivo and homed to inflamed tissue with higher efficiency compared with native MSCs. The modular approach described herein offers a simple method to potentially target any cell type to specific tissues via the circulation.

30 October 2008 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
DSDebanjan Sarkar
Debanjan Sarkar
PVPraveen Kumar Vemula
Praveen Kumar Vemula
GTGrace S. L. Teo
Grace S. L. Teo
DSDawn Spelke
Dawn Spelke
RKRohit Karnik
Rohit Karnik
JKJeffrey M. Karp
Jeffrey M. Karp

12 December 2012 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
MPMaria José Nunes Pereira
Maria José Nunes Pereira
BOBen Ouyang
Ben Ouyang
CSCathryn A. Sundback
Cathryn A. Sundback
NLNora Lang
Nora Lang
IFIngeborg Friehs
Ingeborg Friehs
JKJeffrey M. Karp
Jeffrey M. Karp

9 January 2014 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
JAJames A Ankrum
James A Ankrum
OMOscar R Miranda
Oscar R Miranda
KNKelvin S Ng
Kelvin S Ng
DSDebanjan Sarkar
Debanjan Sarkar
Chenjie XuChenjie Xu
Chenjie Xu
JKJeffrey M Karp
Jeffrey M Karp

2 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XHXiaoning He
Xiaoning He
RDRosemary Dziak
Rosemary Dziak
XYXue Yuan
Xue Yuan
KMKeya Mao
Keya Mao
RGRobert Genco
Robert Genco
SYShuying Yang
Shuying Yang
Current clinical therapies for critical-sized bone defects (CSBDs) remain far from ideal. Previous studies have demonstrated that engineering bone tissue using mesenchymal stem cells (MSCs) is feasible. However, this approach is not effective for CSBDs due to inadequate vascularization. In our previous study, we have developed an injectable and porous nano calcium sulfate/alginate (nCS/A) scaffold and demonstrated that nCS/A composition is biocompatible and has proper biodegradability for bone regeneration. Here, we hypothesized that the combination of an injectable and porous nCS/A with bone morphogenetic protein 2 (BMP2) gene-modified MSCs and endothelial progenitor cells (EPCs) could significantly enhance vascularized bone regeneration. Our results demonstrated that delivery of MSCs and EPCs with the injectable nCS/A scaffold did not affect cell viability. Moreover, co-culture of BMP2 gene-modified MSCs and EPCs dramatically increased osteoblast differentiation of MSCs and endothelial differentiation of EPCs in vitro. We further tested the multifunctional bone reconstruction system consisting of an injectable and porous nCS/A scaffold (mimicking the nano-calcium matrix of bone) and BMP2 genetically-engineered MSCs and EPCs in a rat critical-sized (8 mm) caviarial bone defect model. Our in vivo results showed that, compared to the groups of nCS/A, nCS/A+MSCs, nCS/A+MSCs+EPCs and nCS/A+BMP2 gene-modified MSCs, the combination of BMP2 gene -modified MSCs and EPCs in nCS/A dramatically increased the new bone and vascular formation. These results demonstrated that EPCs increase new vascular growth, and that BMP2 gene modification for MSCs and EPCs dramatically promotes bone regeneration. This system could ultimately enable clinicians to better reconstruct the craniofacial bone and avoid donor site morbidity for CSBDs.